Bio Break: Laboratory Developed Tests vs. In Vitro Diagnostics

Resources

Bio Break: Laboratory Developed Tests vs. In Vitro Diagnostics

Sector: Diagnostics
Topic: Bio Break

In this episode of Bio Break, Joris van der Heijden and Nick Allan dive into the FDA’s new regulations surrounding Laboratory Developed Tests (LDTs) and their impact on the medical device industry. As LDTs grow in complexity, including applications like genetic testing and AI-driven diagnostics, these regulatory changes mark a significant shift for laboratories, developers, and healthcare providers.

Nick, drawing on his experience with medical device development, explains the critical distinctions between LDTs and In Vitro Diagnostics (IVDs). He provides insights into why these changes are happening and what they mean for developers working to bring innovative diagnostic tools to market.

Key takeaways from the episode include:

  • Understanding the Difference: LDTs are clinically validated tests performed in CLIA-approved labs but do not require FDA regulatory clearance, unlike IVDs, which are classified as medical devices.
  • The Shift in Regulation: The FDA is transitioning from selective enforcement to increased scrutiny due to the growing complexity and impact of LDTs, such as cancer diagnostics and genetic testing.
  • Implications for Developers: Nick explores how the new regulations add layers of oversight but also improve the safety, accuracy, and reliability of tests with far-reaching implications for patient care.

Joris and Nick discuss the broader industry impacts, including the challenges and opportunities presented by these regulatory changes. While some pushback is expected, they highlight how these steps are ultimately beneficial for innovation and patient outcomes, ensuring that advanced diagnostics meet higher standards of clinical utility and reliability.

This episode is essential viewing for medical device developers, diagnostic innovators, and healthcare professionals navigating the evolving regulatory landscape. Gain a clear understanding of how the FDA’s increased involvement in LDTs is shaping the future of diagnostics and how to stay ahead in this rapidly changing environment.

Laboratory Developed Tests vs. In Vitro Diagnostics

YouTube video thumbnail

Read our article on the impact of FDA Laboratory Developed Tests 2024 Policy update to its regulatory approach for in vitro diagnostic products (IVDs), including laboratory developed tests (LDTs). 

Magnified view of printed circuit board inspection during PCBA bring-up for medical device prototype development.

PCBA Bring-Up in Medical Device Prototypes

Bringing up a new printed circuit board assembly (PCBA) for a medical device is both exciting and high-stakes.

Engineer testing circuit board for portable medical device design using oscilloscope and microscope in electronics lab.

Design Considerations for Portable Medical Electronics

Several design considerations come into play when designing portable medical electronic devices, from performance, to usability, manufacturability and reliability.

Engineer testing power stability and voltage regulation on medical device PCB using lab instruments and probes.

Precision Power Design in Medical Devices

For many medical devices, power stability isn’t just a nice-to-have, it’s mission-critical.

Thumbnail showing a medical sampling pipette with a red arrow pointing to a microscope under the text “Repurposed for Research?” illustrating medical device adaptation in scientific studies.

Device Repurposing in Research

Nick Allan and Nigel Syrotuck discuss device repurposing in research, sharing a story that blends microbiology, animal science, and engineering ingenuity.